Takeda to Option Alzheimer’s Therapy from AC Immune in $2.2 Billion Deal

Japan’s Takeda acquired global rights to an Alzheimer’s therapy developed by AC Immune SA of Switzerland for $100 million upfront and up to $2.1 billion in milestone payments. With the $100 million, Takeda owns an option to license AC Immune’s active immunotherapies that target toxic forms of amyloid beta (Abeta), including ACI-24.060. ACI-24.060 is an anti-Abeta active immunotherapy candidate aimed at reducing the toxic forms of Abeta believed to drive plaque formation and Alzheimer’s disease progression. Currently, ACI-24.060 is being tested in a double-blind, placebo-controlled Phase Ib/II trial in subjects with mild Alzheimer’s disease and in adults with Down's syndrome. More details....

Stock Symbols: (TSE: 4502; NYSE: TAK) (NSDQ: ACIU)

Share this with colleagues: